A group of investors including led by New Mountain Capital, ARCH Venture Partners and Venrock Associates have financed a merger agreement between Ikaria and INO Therapeutics valued at $670 million. The combined company will be called Ikaria Holdings with a primary focus on therapeutic gases and critical care medicine. Its corporate headquarters will be in Clinton, NJ, with operations in several other locations including a research and development facility in Seattle.
"The merger of Ikaria and INO Therapeutics creates a fully integrated critical care therapeutics company with more than 300 employees, exceptional growth opportunities and the capability to significantly improve critical care for newborns and other patients in thousands of hospitals around the world," said David Shaw, chairman and CEO-designate of the combined Ikaria entity. Ikaria was a 2005 Fierce 15 winner.
- check out the release on the merger